


EXACT Sciences Regains NASDAQ Compliance
MARLBOROUGH, Mass.--([ BUSINESS WIRE ])--EXACT Sciences Corporation (NASDAQ: EXAS) announced today that the Company received a determination from The NASDAQ Stock Market indicating that the Company has evidenced full compliance with all requirements for continued listing on The NASDAQ Capital Market. As a result, the Company's securities will continue to trade on The NASDAQ Capital Market.
As announced on November 26, 2008, the NASDAQ Listing Qualifications Panel determined to list the Company's securities on The NASDAQ Capital Market on a conditional basis, pending its review of additional information regarding the Company's plan to evidence compliance with the requirements for continued listing on that market. The Panel has concluded its review and, based upon the Company's compliance with all listing criteria, has determined to continue the Company's listing on The NASDAQ Capital Market subject to no further conditions.
About EXACT Sciences Corporation
EXACT Sciences Corporation uses applied genomics to develop patient-friendly screening technologies for use in the detection of cancer. EXACT has established a strategic relationship with Genzyme to, among other things, facilitate the development of the Company's next-generation stool-based DNA (sDNA) technology. EXACT maintains an exclusive license agreement in the United States and Canada with Laboratory Corporation of America® Holdings (LabCorp®) for certain intellectual property relating to sDNA screening. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer (a group comprised of representatives from the American College of Gastroenterology, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy), and the American College of Radiology. EXACT Sciences is based in Marlborough, Mass.